Agenus Inc is a biotechnology company based in New York, NY that focuses on harnessing the power of the immune system to develop curative therapies for cancer patients. Their innovative approach includes the development of next-generation antibodies, such as botensilimab, which aims to extend the benefits of immunotherapy to tumors that do not respond to approved treatments. With a diverse portfolio of immunotherapies and vertically integrated capabilities, Agenus is well-positioned to discover and develop effective cancer therapies.
Through partnerships with industry leaders, Agenus has accelerated the development of select programs, generating capital to support their pipeline development. Their team of over 400 employees, spread across offices in the US and Europe, brings together top talent and expertise to advance their mission. Agenus is committed to expanding the patient population benefiting from immunotherapy through combination approaches and the development of a broad repertoire of antibody therapeutics.
Generated from the website